A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

dc.contributor.author	García Campelo, María del Rosario
dc.date.accessioned	2017-06-07T07:12:42Z
dc.date.available	2017-06-07T07:12:42Z
dc.date.issued	2015
dc.identifier.issn	0923-7534
dc.identifier.uri	http://hdl.handle.net/20.500.11940/3872
dc.language.iso	eng
dc.title	A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease
dc.type	Artigo	es
dc.authorsophos	Wolf, J.
dc.authorsophos	Hochmair, M.
dc.authorsophos	Kattan, J. G.
dc.authorsophos	Ang, M. K.
dc.authorsophos	Garon, E. B.
dc.authorsophos	Groen, H. J. M.
dc.authorsophos	Heist, R.
dc.authorsophos	Ohashi, K.
dc.authorsophos	Felip, E.
dc.authorsophos	Reguart, N.
dc.authorsophos	Garcia Campelo, R.
dc.authorsophos	Soo, R.
dc.authorsophos	Paz-Ares, L.
dc.authorsophos	de Marinis, F.
dc.authorsophos	Smit, E. F.
dc.authorsophos	Giovannini, M.
dc.authorsophos	Squires, M.
dc.authorsophos	Cui, X.
dc.authorsophos	Zhang, Y.
dc.authorsophos	Tan, D.
dc.identifier.isi	367158700477
dc.identifier.sophos	18332
dc.issue.number	supl 9
dc.journal.title	ANNALS OF ONCOLOGY
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario A Coruña::Oncoloxía médica
dc.page.initial	146
dc.page.final	146
dc.rights.accessRights	openAccess
dc.typesophos	Artículo de Opinión
dc.volume.number	26

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.